Gynecologic oncologyHumansFemaleCost-Benefit AnalysisEndometrial NeoplasmsTrastuzumab
Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer.
Aya Bashi, Ling Chen, Kevin Rouse, Elena B Elkin, Jennifer S Ferris, Xiao Xu, Nina A Bickell, Stephanie Blank, Emma C Rossi, William D Hazelton, Jason D Wright, Laura J Havrilesky, Evan R Myers
Published: 202510.1016/j.ygyno.2025.09.019
Abstract
OBJECTIVE: To compare cost-effectiveness of targeted therapeutic strategies for non-Hispanic Black (NHB) and non-Hispanic White (NHB) patients with newly diagnosed, advanced-stage endometrial cancer. METHODS: A Markov-based cost-utility model using a…
Preview only. Read the full abstract at the source